Interaction of pefloxacin and enoxacin with the human cytochrome P450 enzyme CYP1A2

Clinical Pharmacology and Therapeutics

Volumn 65, Issue 3, 1999, Pages 262-274

  Kinzig Schippers, Martina ^b   Fuhr, Uwe ^b   Zaigler, Michael ^b   Dammeyer, Jörg ^b   Rüsing, Guido ^b   Labedzki, Andreas ^b   Bulitta, Jürgen ^b   Sörgel, Fritz ^a  

^a IBMP   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE; COUMARIN; CYTOCHROME P450 ISOENZYME; ENOXACIN; ERYTHROMYCIN; FURAFYLLINE; KETOCONAZOLE; NORFLOXACIN; PARAXANTHINE; PEFLOXACIN; PHENACETIN O DEETHYLASE; QUINIDINE;

AREA UNDER THE CURVE; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPETITIVE INHIBITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEMETHYLATION; DISTRIBUTION VOLUME; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME ISOLATION; FEMALE; FOOD DRUG INTERACTION; HUMAN; HUMAN EXPERIMENT; MALE; NEUROLOGIC DISEASE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STEADY STATE;

EID: 0033067792     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(99)70105-0     Document Type: Article

References (57)

1. 1. Sörgel F, Kinzig M. Pharmacokinetics of gyrase inhibitors; II: renal and hepatic elimination pathways and drug interactions. Am J Med 1993;94(suppl 3A):56S-69S.
2. 2. Fuhr U, Strobl G, Manaut F, Anders EM, Sörgel F, Lopez-de-Briñas E, et al. Quinolone antibacterial agents: relationship between structure and in vitro inhibition of the human cytochrome P450 isoform CYP1A2. Mol Pharmacol 1993;43:191-9.
3. 3. Eiermann B, Engel G, Johansson I, Zanger UM, Bertilsson L. The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. Br J Clin Pharmacol 1997;44: 439-46.
4. 4. Spaldin V, Madden S, Adams DA, Edwards RJ, Davies DS, Park BK. Determination of human hepatic cytochrome P4501A2 activity in vitro use of tacrine as an isoenzyme-specific probe. Drug Metab Dispos 1995; 23:929-34.
5. 5. Conri C, Lartigue MC, Abs L, Mestre MC, Vincent MP, Haramburu F, Constans J. Convulsions chez une malade traitée par péfloxacine et théophylline. Thérapie 1990; 45:358.
6. 6. Grasela TH Jr, Dreis MW. An evaluation of the quinolone-theophylline interaction using the Food and Drug Administration spontaneous reporting system. Arch Intern Med 1992;152:617-21.
7. 7. Wijnands WJA, van Herwarden CLA, Vree TB. Enoxacin raises plasma theophylline concentrations. Lancet 1984; 2:108-9.
8. 8. Bem JL, Mann RD. Danger of interaction between ciprofloxacin and theophylline. Br Med J 1988;296:1131.
9. 9. Maesen FP, Teengs JP, Baur C, Davies BI. Quinolones and raised plasma concentrations of theophylline [letter]. Lancet 1984;2:530.
10. 10. Wijnands WJA, Vree TB, van Herwarden CLA. The influence of quinolone derivatives on theophylline clearance. Br J Clin Pharmacol 1986;22:677-83.
11. 11. Fuhr U, Anders EM, Mahr G, Sörgel F, Staib AH. Inhibitory potency of quinolone antibacterial agents against cytochrome P450IA2 activity in vivo and in vitro. Antimicrob Agents Chemother 1992;36:942-8.
12. 12. Harder S, Staib AH, Beer C, Papenburg A, Stille W, Shah PM. 4-Quinolones inhibit biotransformation of caffeine. Eur J Clin Pharmacol 1988;35:651-6.
13. 13. Carbó M, Segura J, De la Torre R, Badenas JM, Camí J. Effect of quinolones on caffeine disposition. Clin Pharmacol Ther 1989;45:234-40.
14. 14. Sarkar MA, Hunt C, Guzelian PS, Karnes HT. Characterization of human liver cytochromes P-450 involved in theophylline metabolism. Drug Metab Dispos 1992; 20:31-7.
15. 15. Tjia JF, Colbert J, Back DJ. Theophylline metabolism in human liver microsomes: inhibition studies. J Pharmacol Exp Ther 1996;276:912-7.
16. 16. Fuhr U, Rost KL, Engelhardt R, Sachs M, Liermann D, Belloc C, et al. Evaluation of caffeine as a test drug for CYP1A2, NAT2 and CYP2E1 phenotyping in man by in vivo by versus in vitro correlations. Pharmacogenetics 1996;6:159-76.
17. 17. Fuhr U, Wolff T, Harder S, Schymanski P, Staib AH. Quinolone inhibition of cytochrome P-450-dependent caffeine metabolism in human liver microsomes. Drug Metabol Dispos 1990;18:1005-10.
18. 18. Mahr G, Sörgel F, Grannemann GR, Kinzig M, Muth P, Patterson K, et al. Effects of temafloxacin and ciprofloxacin on the pharmacokinetics of caffeine. Clin Pharmacokinet 1992;22(suppl 1):90-7.
19. 19. Jaehde U, Sörgel F, Stephan U, Schunack W. Effect of an antacid containing magnesium and aluminum on absorption, metabolism, and mechanism of renal elimination of pefloxacin in humans. Antimicrob Agents Chemother 1994;38:1129-33.
20. 20. Jaehde U, Sörgel F, Naber KG, Zürcher J, Schunack W. Distribution kinetics of enoxacin and its metabolite oxoenoxacin in excretory fluids of healthy volunteers. Antimicrob Agents Chemother 1995;39:2092-7.
21. 21. Hardman JG, Gilman AG, Limbird LE, editors. Goodman and Gilman's the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill; 1996.
22. 22. Steinijans VW, Hartmann M, Huber R, Radtke HW. Lack of pharmacokinetic interaction as an equivalence problem. Int J Clin Pharmacol TherToxicol 1991;29:323-8.
23. 23. Tassaneeyakul W, Birkett DJ, Veronese ME, McManus ME, Tukey RH, Miners JO. Direct characterization of the selectivity of furafylline as an inhibitor of human cytochromes P450 1A1 and 1A2. Pharmacogenetics 1994;4:281-4.
24. 24. Ono S, Hatanaka T, Hotta H, Satoh T, Gonzalez FJ, Tsutsui M. Specificity of substrate and inhibitor probes for cytochrome P450s: evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes. Xenobiotica 1996;26:681-93.
25. 25. Correia MA. Rat and human liver cytochromes P450: Substrate and inhibitor specificities and functional markers. In: Ortiz de Montellano P, editor. Cytochrome P450: structure, mechanism and biochemistry. 2nd ed. New York and London: Plenum Press; 1995. p. 607-30.
26. 26. Frydman AM, Le Roux Y, Lefebvre MA, Djebbar F, Fourtillan JB, Gaillot J. Pharmacokinetics of pefloxacin after repeated intravenous and oral administration (400 mg bid) in young healthy volunteers. J Antimicrob Chemother 1986;17(suppl B):65-79.
27. 27. Sörgel F, Naber KG, Stephan U. Pharmakokinetik und Analytik von Gyrasehemmern. Fortschritte der antimikrobiellen and antineoplastischen Chemotherapie 1987;6-10:1907-61.
28. 28. Bressolle F, Gonçalves F, Gouby A, Galtier M. Pefloxacin clinical pharmacokinetics. Clin Pharmacokinet 1994;27: 418-46.
29. 29. Staib AH, Harder S, Mieke S, Beer C, Stille W, Shah P. Gyrase inhibitors impair caffeine elimination in man. Methods Find Exp Clin Pharmacol 1987;9:193-8.
30. 30.Healy DP, Polk RE, Kanawati L, Rock DT, Mooney ML. Interaction between oral ciprofloxacin and caffeine in normal volunteers. Antimicrob Agents Chemother 1989; 33:474-8.
31. 31. Nicolau DP, Nightingale CH, Tessier PR, Fu Q. Xuan DW, Esguerra EM, et al. The effect of fleroxacin and ciprofloxacin on the pharmacokinetics of multiple dose caffeine. Drugs 1995;49(suppl 2):357-59.
32. 32. Parker AC, Preston T, Heaf D, Kitteringham NR, Choonara I. Inhibition of caffeine metabolism by ciprofloxacin in children with cystic fibrosis as measured by the caffeine breath test. Br J Clin Pharmacol 1994; 38:573-6.
33. 33. Vincent J, Teng R, Dogolo LC, Willavize SA, Friedman HL. Effect of trovafloxacin, a new fluoroquinolone antibiotic, on the steady-state pharmacokinetics of theophylline in healthy volunteers. J Antimicrob Chemother 1997;39 (suppl B):81-6.
34. 34. Efthymiopoulos C, Bramer SL, Maroli A, Blum B. Theophylline and warfarin interaction studies with grepafloxacin. Clin Pharmacokinet 1997;33(suppl 1):39-46.
35. 35. Fuhr U, Doehmer J, Battula N, Wölfel C, Flick I, Kudla C. Biotransformation of methylxanthines in mammalian cell lines genetically engineered for expression of single cytochrome P450 isoforms: allocation of metabolic pathways to isoforms and inhibitory effects of quinolones. Toxicology 1993;82:169-89.
36. 36. Sörgel F, Mahr G, Koch HU, Stephan U, Wiesemann HG, Malter U. Effects of cimetidine on the pharmacokinetics of pefloxacin in healthy volunteers [abstract]. Rev Infect Dis 1988;10(suppl 1):137.
37. 37. Jaehde U, Malter U, Sörgel F, Gottschalk B, Wiesemann H, Stephan U, Höffler D, Schunack W. Individual factors affecting the pharmacokinetics of pefloxacin. In: Berkarda B, Kuemmerle HP, editors. Progress Antimicrob Anticancer Chemother: Proceedings of the 15th International Congress of Chemotherapy. July 19-24, 1987, Istanbul/Turkey. Landsberg: Ecomed-Verlagsgesellschaft GmbH, 1987:883-5.
38. 38. Sörgel F. Metabolism of gyrase inhibitors. Rev Infect Dis 1989;11(suppl 5):S1119-29.
39. 39. Rasmussen BB, Brøsen K. Determination of urinary metabolites of caffeine for the assessment of cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activity in humans. Ther Drug Monit 1996;18:254-62. s
40. 40. Mizuki Y, Fujiwara I, Yamaguchi T. Pharmacokinetic interactions related to the chemical structures of fluoroquinolones. J Antimicrob Chemother 1996;37(suppl A): 41-55.
41. 41. Nordmann P, Pechinot A, Kazmierczak A. Cytotoxicity and uptake of pefloxacin, ciprofloxacin, and ofloxacin in primary cultures of rat hepatocytes. J Antimicrob Chemother 1989;24:355-63.
42. 42. Une T, Osada Y. Penetrability of ofloxacin into cultured epithelial cells and macrophages. Arzneimittelforschung 1988;38:1265-7.
43. 43. Perea EJ, Garcia I, Pascual A. Comparative penetration of lomefloxacin and other quinolones into human phagocytes. Am J Med 1992;92(Suppl 4A):48S-51S.
44. 44. Sörgel F, Kinzig M. Pharmacokinetics of gyrase inhibitors; I: basic chemistry and gastrointestinal disposition. Am J Med 1993;94(suppl 3A):44S-55S.
45. 45. Zlotos G, Bücker A, Kinzig-Schippers M, Sörgel F, Holzgrabe U. Plasma protein binding of gyrase inhibitors. J Pharm Sci 1998;87:215-20.
46. 46. Memin E, Panteix G, Revol A. Is the uptake of pefloxacin in human blood monocytes a simple diffusion process? J Antimicrob Chemother 1996;38:787-98.
47. 47. Sasabe H, Kato Y, Tsuji A, Sugiyama Y. Stereoselective hepatobiliary transport of the quinolone antibiotic grepafloxacin and its glucuronide in the rat. Pharmacol Exp Ther 1998;284:661-8.
48. 48. Holmes B, Brogden RN, Richards DM. Norfloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 1985;30:482-513.
49. 49. Phillips I, King A. Comparative activity of the 4-quinolones. Rev Infect Dis 1988;10(suppl 1):S70-6.
50. 50. Andrejak M, Schmit JL, Tondriaux A, Hary L, Debailleux S, Moore N. Effects indésirables neurologiques des fluoroquinolones: a propos de 9 observations concernant la péfloxacine. Thérapie 1992;47:415-8.
51. 51. Ball P. Adverse reactions and interactions of fluoroquinolones. Clin Invest Med 1989;12:28-34.
52. 52. Gonzalez JP, Henwood JM. Pefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 1989;37:628-68.
53. 53. Janknegt R. Fluoroquinolones: adverse reactions during clinical trials and postmarketing surveillance. Pharm Weekbl(Sci) 1989;11:124-7.
54. 54. Zaigler M, Fuhr U. In vivo vs in vitro comparison of inhibitory drug effects on the human cytochrome P450 isoform CYP1A2 [abstract]. Eur J Clin Pharmacol 1994;47:120.
55. 55. Brøsen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S. Fuvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 1993;45:1211-4.
56. 56. Loi CM, Parker BM, Cusack BJ, Vestal RE. Aging and drug interactions; III: individual and combined effects of cimetidine and cimetidine and ciprofloxacin on theophylline metabolism in healthy male and female nonsmokers. J Pharmacol Exp Ther 1997;280:627-37.
57. 57. Tarrus E, Cami J, Roberts DJ, Spickett RGW, Celdran E, Segura J. Accumulation of caffeine in healthy volunteers treated with furafylline. Br J Clin Pharmacol 1987;23: 9-18.